Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm cuts jobs in cost savings move
With the completion of enrollment in the pivotal phase III PRECISE clinical trial for the company’s lead drug product candidate, cintredekin besudotox, NeoPharm said that it is now
With the completion of enrollment in the pivotal phase III PRECISE clinical trial for the company’s lead drug product candidate, cintredekin besudotox, NeoPharm said that it is now
The study will examine women’s blood for a number of cancer related biomarkers, which are specific proteins having concentrations that are measurably different in patients with breast cancer.
Previously referred to as DepoMorphine, DepoDur is a novel single dose sustained-release injectable formulation of morphine designed for the control of pain after major surgery. SkyePharma expects that
The positive opinion is for Sutent (sunitinib malate) in metastatic renal cell carcinoma (mRCC) after failure of interferon alpha or interleukin-2-based therapy. The positive opinion was also granted
The positive opinion is for Tysabri (natalizumab) as a treatment for relapsing-remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses. The
Tapentadol (CG5503/ R331333) is a novel, centrally acting analgesic with a dual mechanism of action developed by German pharmaceutical company Grunenthal. Ortho-McNeil Pharmaceutical entered into a licensing agreement
The European Commission decision regarding marketing authorization for Kaletra (lopinavir/ritonavir) is expected within 90 days. The anticipated marketing authorization from the European Commission also will enable Abbott to
The randomized, open-label trial tested the clinical potential of the drug in patients with stage IIIB and IV non-small cell lung cancer (NSCLC). The analysis confirms a median
The positive opinion is based on results from a phase III clinical trial named ATLAS. In October 2005, Abbott submitted a supplemental biologics license application (sBLA) with the
Importantly, the shorter 24-week regimen was also associated with a low rate of relapse – only 6% in genotype 2 patients and 10% in genotype 3 patients, which